3.58 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||3.41 x 600|
|Ask||4.00 x 600|
|Day's Range||3.55 - 3.65|
|52 Week Range||2.58 - 5.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.36|
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Investors in Achillion Pharmaceuticals (ACHN) need to pay close attention to the stock based on moves in the options market lately.
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]
NEW YORK, March 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEW HAVEN, Conn., March 08, 2018-- Achillion Pharmaceuticals, Inc. announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays ...
Investing in cheap stocks can be risky and inexperienced investors are usually advised to stay clear of them, even though many new investors go straight to cheap stocks hoping to score big. Of course, in case of a successful investment, the returns can indeed be very big, given that cheap stocks are prone to bigger […]
RTW Investments of New York is focused on the health-care sector and its portfolio, valued at $1.1 billion, according to S&P Capital IQ, is populated with many smaller drug developers. In the fourth quarter, the hedge fund made some interesting investment changes in names that had big moves in 2017, including two that tripled in value. RTW exited bluebird bio (BLUE) entirely and initiated a position in Vericel (VCEL).
February 28, 2018 is the 11 th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the kidneys ...
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares rise more than 15% on the day.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / U.S. markets rose for the third consecutive session on Monday on the strength of technology shares. The Dow Jones Industrial Average spiked 1.58 percent ...
Stock Monitor: Achillion Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Bellicum Pharma, Inc. (NASDAQ: BLCM ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Vista Outdoor Inc (NYSE: VSTO ) stock along with other ...
NEW HAVEN, Conn., Feb. 26, 2018-- Achillion Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the complement alternative pathway, today ...
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) trackRead More...
The New Haven, Connecticut-based company said it had a loss of 17 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief Operating ...
NEW HAVEN, Conn., Feb. 09, 2018-- Achillion Pharmaceuticals, Inc. announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will participate in a fireside chat at ...
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.